eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference
eFFECTOR Therapeutics (NASDAQ: EFTR) will participate in a panel discussion at the Cantor Oncology, Hematology, HemeOnc Conference on September 28, 2022, from 10:40 AM ET to 11:20 AM ET. The panel is titled “Building Combinations: What are the Novel Ideas?” and will feature Steve Worland, Ph.D., President and CEO. eFFECTOR is focused on developing selective translation regulator inhibitors (STRIs) for cancer treatment, with ongoing trials for lead candidate tomivosertib and zotatifin. For more details, visit: Cantor Conference.
- None.
- None.
- Presentation Scheduled for Wednesday, September 28 from 10:40-11:20 AM ET -
SAN DIEGO and REDWOOD CITY, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the Company will participate in a panel discussion and host 1x1 meetings at the upcoming Cantor Oncology, Hematology, HemeOnc Conference.
Panel Topic: | “Building Combinations: What are the Novel Ideas?” |
Date: | Wednesday, September 28, 2022 |
Time: | 10:40 AM ET |
Panel Participant: | Steve Worland, Ph.D., President and Chief Executive Officer |
Conference Website | https://www.cantor.com/cantor-oncology-hemonc-conference/ |
About eFFECTOR Therapeutics
eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR’s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes. Each of eFFECTOR’s product candidates is designed to act on a single protein that drives the expression of a network of functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR’s lead product candidate, tomivosertib, is a MNK inhibitor currently being evaluated in KICKSTART, a randomized, double-blind, placebo-controlled Phase 2b trial of tomivosertib in combination with pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC). Zotatifin, eFFECTOR’s inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E. In addition to the company’s oncology focus, zotatifin is being evaluated as a potential host-directed anti-viral therapy in patients with mild to moderate COVID-19 in collaboration with the University of California, San Francisco, under a
Contacts:
Investors: | Media: | |
Christopher M. Calabrese Managing Director LifeSci Advisors 917-680-5608 ccalabrese@lifesciadvisors.com | Kevin Gardner Managing Director LifeSci Advisors 617-283-2856 kgardner@lifesciadvisors.com | Heidi Chokeir, Ph.D. Managing Director Evoke Canale 619-203-5391 Heidi.chokeir@evokegroup.com |
FAQ
When is eFFECTOR Therapeutics speaking at the Cantor Oncology Conference?
Who will represent eFFECTOR Therapeutics at the conference?
What is the focus of the panel discussion at the Cantor Oncology Conference?
What is the ticker symbol for eFFECTOR Therapeutics?
What does eFFECTOR Therapeutics specialize in?